MORRISON & FOERSTER LLP

ATTORNEYS AT LAW

SAN FRANCISCO
LOS ANGELES
SACRAMENTO
ORANGE COUNTY
PALO ALTO
WALNUT CREEK
DENVER

2000 PENNSYLVANIA AVENUE, NW WASHINGTON, D.C. 20006-1888 TELEPHONE (202) 887-1500 TELEFACSIMILE (202) 887-0763 November 1, 1999 NEW YORK
LONDON
BRUSSELS
BEIJING
HONG KONG

Receipt for

Certified Mail
No Insurance Coverage Provided
Do not use for International Mail
(See Reverse)

Dr. Ann Monosov 1715 Edgefield Lane Encinitas, CA 92024-1977

Re: U.S. Patent Application No. 09/023,231
Title: NUDE MOUSE MODEL FOR NEOPLAST

By: Ann MONOSOV et al. Our Reference: 31276-20014.30

U.S. Patent Application No. 09/023,232

Title: NUDE MOUSE MODEL FOR HUMAN NE

DISEASE

By: Ann MONOSOV et al.

Our reference: 31276-20015,30

Dear Dr. Monosov:

This letter is further to my letter to you dated September 13th, I requested your assistance in signing Reissue Application

Declarations and Powers of Attorney to be filed on behalf of AntiCancer, Incorporated in the two above identified patent applications.

I further pointed out that we have not been able to locate Dr. Xinyu Fu to obtain his signature on these declarations. Provisions of the patent statutes provide that all joint inventors are required to execute the oath or declaration in a subject patent application in order to perfect the filing date. However, where one or more joint inventors refuses to sign or can not be located, the application may be made by the remaining inventor(s) who is permitted to execute the oath or declaration on behalf of himself or herself and the nonsigning inventor.

Therefore, I have enclosed copies of Reissue Application Declarations and Powers of Attorney that have been amended to provide that you are signing on behalf of yourself as well as the nonsigning inventor, Dr. Xinyu Fu. Would you please review and sign each document as indicated and return these originally signed documents to our office at your earliest possible opportunity?

official trace on this piece of mail. On or about May 13, 1999, I completed and filed a USPS Form 3811A with the USPS.

- On July 30, 1999, I inquired of the USPS (at telephone: 202-523-2188) as to the status of my request provided in the completed Form 3811A. I was informed that I should contact USPS Consumer Affairs. On August 3, 1999, I contacted USPS Consumer Affairs and spoke with Ms. D. Simmons, Consumer Affairs Representative who said she would conduct a thorough investigation and respond to my inquiry on the status of delivery of the Certified Mail (certificate No.; Z 526 279 102).
- On August 17, 1999, I received a letter from Ms. D. Simmons informing me that, 14 after a thorough investigation, the USPS was unable to locate any record for Certified Article Z 526 279 102. Ms. Simmons surmised that the return receipt had apparently become separated from the article while being processed through their system and the envelope may have been delivered as ordinary first-class Mail. (Ms. Simmons enclosed \$4.29 in postage to compensate us for the loss of postage, since we did not receive the service for which we paid.)
- On September 13, 1999, I prepared a package for delivery by the USPS as Certified Mail (certificate No.: P 885907685). I addressed this package to: Dr. Ann Monosov, 1715 Edgefield Lane; Encinitas, CA 92024-1977. This package contained the herein application Declaration prepared by Thomas D. Mays for signature by Dr. Ann Monosov on her own behalf and on behalf of the remaining joint inventor, Dr. Xinyu Fu. Also on September 13, 1999, I deposited this package with the USPS.
- As evidenced by the return receipt postcard, Dr. Monosov received this package 16. on September 18, 1999.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

4

Date R. Lynn Criz